Overview: Insulin-Like Growth Factor Binding Protein 2 TestIntroduction: The Insulin-Like Growth Factor Binding Protein 2 Test measures IGFBP-2 to assess growth or metabolic disorders, causing fatigue or growth issues. Aligned with 2023 Endocrine Society guidelines, it uses immunoassays for high accuracy, supporting endocrine screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in endocrinology for patients with suspected metabolic or growth disorders.
Other Names: IGFBP-2 Assay, IGF Binding Protein-2 Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: IGFBP-2 testing began in the 1990s with growth hormone research. Immunoassay-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures IGFBP-2 to diagnose growth or metabolic disorders, guides treatment, and evaluates patients with fatigue or growth issues.
Test Parameters: 1. IGF Binding Protein-2
Pretest Condition: Fasting for 10-12 hours required. Collect serum or plasma in the morning. Report history of growth issues, fatigue, or metabolic disorders.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, growth issues, or metabolic disorders (e.g., diabetes, pituitary dysfunction). Include current medications, especially hormone therapies.
Consent: Written consent required, detailing the tests purpose, metabolic disorder implications, and potential need for treatment planning.
Procedural Considerations: Uses immunoassays to measure IGFBP-2 levels. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for metabolic assessment.
Factors Affecting Result Accuracy: Non-fasting samples, improper handling, or certain medications (e.g., insulin) can affect results. Hemolysis may interfere with accuracy.
Clinical Significance: Abnormal IGFBP-2 levels suggest growth or metabolic disorders, guiding hormone or metabolic therapy. Normal levels may require further endocrine testing.
Specialist Consultation: Consult an endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: IGF-I, IGFBP-3, or glucose tolerance test to assess metabolic or growth disorders.
Test Limitations: IGFBP-2 levels vary with nutrition and age; clinical correlation is needed. Not specific to one disorder.
References: Endocrine Society Growth Hormone Guidelines, 2023; Journal of Clinical Endocrinology, Clemmons DR, 2022.
